ATRC Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of -12.53% compared to AtriCure's net margin of -0.81%. AtriCure's return on equity of -9.67% beat iRhythm Technologies's return on equity of -100.75%.

AtriCure has a consensus price target of $51.22, signalling upside risk potential of 71.26%. On the other hand iRhythm Technologies has an analysts' consensus of $130.92 which suggests that it could grow by 22.48%. Given that AtriCure has higher upside potential than iRhythm Technologies, analysts believe AtriCure is more attractive than iRhythm Technologies.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.347%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $124.3M, which are smaller than iRhythm Technologies quarterly revenues of $164.3M. AtriCure's net income of -$15.6M is lower than iRhythm Technologies's net income of -$1.3M. Notably, AtriCure's price-to-earnings ratio is -- while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.02x versus 5.63x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -12.53% compared to AtriCure's net margin of 30.99%. AtriCure's return on equity of -9.67% beat Intuitive Surgical's return on equity of 15.82%.

AtriCure has a consensus price target of $51.22, signalling upside risk potential of 71.26%. On the other hand Intuitive Surgical has an analysts' consensus of $576.03 which suggests that it could grow by 11.68%. Given that AtriCure has higher upside potential than Intuitive Surgical, analysts believe AtriCure is more attractive than Intuitive Surgical.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $124.3M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. AtriCure's net income of -$15.6M is lower than Intuitive Surgical's net income of $698.4M. Notably, AtriCure's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 75.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.02x versus 21.49x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -12.53% compared to AtriCure's net margin of -5.14%. AtriCure's return on equity of -9.67% beat Integer Holdings's return on equity of 4.85%.

AtriCure has a consensus price target of $51.22, signalling upside risk potential of 71.26%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 17.07%. Given that AtriCure has higher upside potential than Integer Holdings, analysts believe AtriCure is more attractive than Integer Holdings.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $124.3M, which are smaller than Integer Holdings quarterly revenues of $437.4M. AtriCure's net income of -$15.6M is higher than Integer Holdings's net income of -$22.5M. Notably, AtriCure's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 59.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.02x versus 2.55x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of -12.53% compared to AtriCure's net margin of 20.07%. AtriCure's return on equity of -9.67% beat LeMaitre Vascular's return on equity of 13.81%.

AtriCure has a consensus price target of $51.22, signalling upside risk potential of 71.26%. On the other hand LeMaitre Vascular has an analysts' consensus of $105.63 which suggests that it could grow by 16.4%. Given that AtriCure has higher upside potential than LeMaitre Vascular, analysts believe AtriCure is more attractive than LeMaitre Vascular.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.076%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.75% to investors and pays a quarterly dividend of $0.20 per share. AtriCure pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AtriCure quarterly revenues are $124.3M, which are larger than LeMaitre Vascular quarterly revenues of $55.7M. AtriCure's net income of -$15.6M is lower than LeMaitre Vascular's net income of $11.2M. Notably, AtriCure's price-to-earnings ratio is -- while LeMaitre Vascular's PE ratio is 46.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.02x versus 9.40x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.